Clinical Trials Logo

Filter by:
NCT ID: NCT03396042 Completed - Eye Diseases Clinical Trials

Natural History Study of CEP290-Related Retinal Degeneration

Start date: December 17, 2017
Phase:
Study type: Observational

A prospective natural history study with systematic assessments and uniform follow-up to provide a high-quality dataset for assisting in the design of future clinical treatment trials involving patients with CEP290-related retinal degeneration caused by the common intron 26 mutation.

NCT ID: NCT03395951 Completed - Heart Failure Clinical Trials

Mean Systemic Filling Pressure Continuous Diuretics Critical Care Patients

Start date: October 1, 2014
Phase:
Study type: Observational

Within clinical settings observation of hemodynamic changes (e.g. mean systemic filling pressure, cardiac output) in critically ill patients with a clinical indication for deresuscitation with intravenous diuretic therapy.

NCT ID: NCT03395236 Completed - Clinical trials for Peripheral Arterial Disease

ILLUMENATE Below-The-Knee (BTK) Arteries: a Post Market Clinical Study

BTK PMS
Start date: April 20, 2018
Phase: Phase 4
Study type: Interventional

The objective of this prospective, multi-center, single arm study is to obtain further data on the safety and performance of the StellarexTM 0.014" OTW Drug-coated Angioplasty Balloon in the treatment of lesions in "below the knee" popliteal (P3 segment) and infra-popliteal arteries according to the Instructions for Use in Rutherford-Becker Classification (RCC) 3, 4 and 5 patient populations. This study will be conducted in Europe across up to 10 centers in up to 75 subjects. Office visits will occur at 30 days, 6, 12, and 24 months post-index procedure.

NCT ID: NCT03395210 Active, not recruiting - Clinical trials for Immune Thrombocytopenia

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

Start date: March 22, 2018
Phase: Phase 2
Study type: Interventional

This is a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/μL on two counts no sooner than 7 days apart in the 15 days before treatment begins. The dose-finding portion of the study has been completed. Part B treatment dose is 400 mg twice daily.

NCT ID: NCT03394924 Completed - Clinical trials for Primary Biliary Cholangitis

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Start date: December 27, 2017
Phase: Phase 2
Study type: Interventional

A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis

NCT ID: NCT03394716 Terminated - Brain Tumor Clinical Trials

Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors

Start date: January 12, 2018
Phase:
Study type: Observational [Patient Registry]

This study aims to evaluate anatomical and functional changes during RT for patients receiving fractionated RT for brain tumors. Anatomical changes during RT will be registered and analyzed and if needed the radiotherapy plan will be modified for the individual patient. This means that the "to be irradiated volume" will be modified according to the shape changes of the tumor. The functional MRI sequences will be used to evaluate what parameters, and at which time point, are important for radiotherapy outcome.

NCT ID: NCT03394638 Recruiting - Obesity Clinical Trials

Assessing the Value of eHealth for Bariatric Surgery

BePATIENT
Start date: February 21, 2017
Phase: N/A
Study type: Interventional

Bariatric surgery is the only treatment with long standing effect of morbid obesity. The key elements to success are the patient-selection, an experienced bariatric team and a completed follow-up program. Follow-up programs can consist of, for example, providing social support in support groups, teaching psychological skills, such as coping with the body change or teaching self-regulation of body weight. Furthermore, follow-up is important for dietary and sports counselling. The experience of the team members and coaching skills are essential in indicating the suitable procedure if necessary and guide the patients through the process. Various studies showed a significant positive effect of a completed follow-up program after bariatric surgery on maintaining weight loss. There is a burden for this on site provided care as organizational and financial resources are not unlimited. Especially as the follow-up period is an obligatory 5 years or if possible life long. Even if this aftercare is provided, not all patients complete the complete program. Various reasons are possible for an increasing no-show-rate, the loss of enthusiasm for onsite visits could be one of them. Analogue to other chronic diseases, the addition of telehealth could be useful. Telehealth is the delivery of health-related services and information via telecommunications technologies. It encompasses preventative, promotive and curative aspects. Examples are exchanging health services or education via videoconference, transmission of medical data for disease management (remote monitoring) and advice on prevention of diseases and promotion of good health by patient monitoring and follow-up. The participation of eHealth has been investigated and considered useful in the treatment of obesity. In a systematic review self-measured blood pressure monitoring was associated with better control of hypertension at least in the first year. Its value in a bariatric tract has not been investigated. It can be hypothesized that self-control by eHealth could enhance clinical outcome as more weight loss and comorbidity reduction. Long-term realistic goals setting, consistent use of routines and self-monitoring has been proven effective for weight loss maintenance. Patients with higher self-control are more certain regarding their abilities, which cause higher commitment and adherence to the program. This eventually leads to more weight loss. For this purpose an online monitoring program was designed for our Obesity Centre (BePATIENT) to provide preoperative information as well as aids in the post-bariatric phase by self-control wireless devices for registration of biometric outcomes, teleconference opportunities and access to additional information. In a prospective trial the implementation in several degrees is evaluated.

NCT ID: NCT03394612 Active, not recruiting - Skin Wound Clinical Trials

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children

Start date: February 14, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial aims to evaluate the efficacy and safety of EHSG-KF (synonym denovoSkin) in comparison to meshed STSG in adults and children with full-thickness Skin defects.

NCT ID: NCT03393871 Completed - Clinical trials for Coronary Artery Disease

Myocardial Mass Determination by FFRct and Absolute Coronary Blood Flow

MyoMass
Start date: February 1, 2018
Phase:
Study type: Observational

The background for performing the present study is to compare the mass calculations by CT scanning and by invasive absolute blood flow measurements and thereby corroborating both methods.

NCT ID: NCT03393806 Terminated - Asthma Clinical Trials

Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)

Start date: April 18, 2018
Phase: Phase 2
Study type: Interventional

This study is multicenter, double-blinded parallel group design, where participants with moderate to severe asthma with AFAD will be enrolled. Participants will receive three doses of 10 milligrams/kilogram (mg/kg) of GSK3772847 every 4 Weeks versus placebo along with standard of care. Participants will be randomized in 1:1 ratio to receive either 10 mg/kg GSK3772847 intravenously (IV) or matching placebo IV. Participants will receive study treatment on Week 0 (Day 1), Week 4 and Week 8. The total duration of the study will be 28 Weeks and approximately 46 participants will be randomized.